<DOC>
	<DOCNO>NCT00395018</DOCNO>
	<brief_summary>The purpose clinical research study learn study drug entecavir prevent recurrence hepatitis B virus ( HBV ) participant receive orthotopic liver transplant ( OLT ) due HBV infection .</brief_summary>
	<brief_title>Antiviral Activity Entecavir Patients Receiving Liver Transplant Due Chronic Hepatitis B Virus Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Patients receive orthotopic liver transplant ( OLT ) due endstage liver disease chronic HBV infection , HBVDNA &lt; 172 IU/mL ( approximately &lt; 1000 copies/mL ) prior liver transplant Must detectable hepatitis B surface antigen ( HBsAg ) screen least 24 week prior screen Patients hepatocellular carcinoma evidence extrahepatic spread , multiple tumor ≥ 6.5 cm diameter three nodule ≥ 4.5 cm diameter total tumor diameter ≥ 8 cm Coinfection human immunodeficiency virus ( HIV ) , cytomegalovirus ( CMV ) , EpsteinBarr virus ( EBV ) hepatitis C virus ( HCV )</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Chronic Hepatitis B Virus , Liver Transplant</keyword>
</DOC>